Is Glucosamine Mobility Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Glucosamine Mobility Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - To ensure a robust synthesis of evidence, we conducted a systematic search of PubMed, Embase, and Web of Science (2020-2025) for high-quality clinical trials, meta-analyses, and guidelines. [Wang H (2026); evidence level 4] - This narrative review evaluates the clinical transition from reactive, surgery-centric models to a proactive, integrated framework to mitigate the profound socioeconomic burden and functional decline associated with the disease. [Wang H (2026); evidence level 4] - We synthesized evidence across non-pharmacological rehabilitation, pharmacotherapy, and advanced joint-preserving surgeries, emphasizing optimal intervention windows and stage-specific mechanobiological requirements. [Wang H (2026); evidence level 4] - Knee osteoarthritis (KOA) is a primary driver of global disability, currently affecting over 365 million adults, with projections suggesting a 74.9% increase by 2050. [Wang H (2026); evidence level 4] - It causes chronic pain, reduced mobility, and disability, affecting 607 million individuals worldwide, with nearly 46.6 million new cases annually []. [Muacevic Alexander (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.